BLA RTF Impact on Share Price Not so sure on a
Post# of 148169
Not so sure on a significant drop as the last two days trading have priced in a delay for HIV around -20% and the speculation around success in COVID trials remains in play with up-listing to NASDAQ contingent on the later.
Regarding the BLA RTF letter if supplemental documentation related to chemistry, manufacturing and controls rather than new clinical or preclinical data is required the delays I have seen in instances like this in the past have induced a 2-3 month delay. An example is this one in May 2020 was a Bristol-Myers Squibb cancer drug, see below.
https://medcitynews.com/2020/05/bluebird-bms-...oma-car-t/